NEW YORK (GenomeWeb News) – Nextcode Health officially launched today, saying it has licensed technology developed by Decode Genetics that it will use to accelerate the diagnosis of cancer through sequencing-based data.

The Cambridge, Mass.-based company also said that it has secured $15 million in Series A financing. Investors in the round included Polaris Partners and Arch Venture Partners, and the financing will be used to scale up the integration of its genomics services into clinical settings.

A Nextcode spokesperson confirmed the company is a spinout of Decode.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genomic study of group B Streptococcus evolution, selection on the X chromosome in great apes, and more.

Changing the fat and fiber content of people's diets affects their gut microbiome, metabolome, and colon cancer risk, researchers say.

Broken links are found throughout academic publications, and some services are trying to combat such link decay.

Nick Stockton at Wired says that a pause in studying genome-editing tools should be used to find a path forward.

May
28
Sponsored by
PerkinElmer

This online seminar will demonstrate how RNA-seq analysis in a model organism can provide insights into human disease.